myasthenia gravis (MG)

View All

Myasthenia gravis market
Myasthenia gravis Market Outlook

Myasthenia gravis (MG) is an autoimmune syndrome that causes weakness in the skeletal muscles caused due to the failure of neuromuscular transmission. Communication between nerve cells and muscles becomes hampered, thus preventing crucial muscles from contracting. This impairment in results from the binding of auto...

Find More

Myasthenia gravis (MG)
Myasthenia Gravis

https://www.slideshare.net/DelveInsight/myasthenia-gravis-126250701?qid=b9adbccf-6d91-4e5e-84e1-7603c87a029e&v=&b=&from_search=1 Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved i...

Find More

alzheimer's
Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M

Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...

Find More